Why Is TG Therapeutics (TGTX) Up 4.7% Since Last Earnings Report?

TG Therapeutics (TGTX) reported mixed Q2 2025 results, with earnings of $0.17 per share missing consensus, while revenues surged 92% year-over-year to $141.1 million, beating estimates, driven by robust Briumvi sales. The company subsequently raised its full-year 2025 revenue guidance to $585 million, up from $575 million, citing continued Briumvi growth. Despite a 4.7% stock gain since the report, analyst estimates have broadly trended downward, resulting in a Zacks Rank #3 (Hold) and an outlook for in-line returns.

Analysis

TG Therapeutics (TGTX) presents a mixed financial profile following its Q2 2025 results, characterized by robust top-line growth set against significant profitability concerns and cautious analyst sentiment. The company's revenue surged 92% year-over-year to $141.1 million, beating the Zacks Consensus Estimate, driven almost entirely by its sole commercial product, Briumvi, which saw sales increase 91% YoY. This strong performance prompted management to raise full-year 2025 revenue guidance to approximately $585 million. However, this impressive growth was overshadowed by a substantial earnings miss, with EPS of 17 cents falling far short of the 32-cent consensus estimate. This profitability gap is compounded by escalating costs, as R&D and SG&A expenses climbed 83.3% and 36.8% respectively. Despite the stock's 4.7% gain since the report, a critical counter-signal has emerged from the analyst community, with consensus estimates being revised downwards by 5.38%. This divergence between management's optimism and analysts' caution, reflected in a Zacks Rank #3 (Hold) and poor VGM scores for Value (D) and Momentum (F), suggests the market is weighing Briumvi's sales momentum against underlying profitability challenges and expects in-line returns.

Key Decisions for Investors

• Investors should weigh the strong top-line momentum, evidenced by the 92% YoY revenue growth and increased full-year guidance, against the significant Q2 earnings miss and rising operating expenses.
• The downward revision of analyst consensus estimates by 5.38% post-earnings, despite raised company guidance, serves as a key red flag, warranting scrutiny of future margin potential and the sustainability of Briumvi's growth.
• Given the stock's 'Hold' rating and poor scores for Value and Momentum, current holders may consider if the recent 4.7% price appreciation presents an opportunity to re-evaluate their position, as near-term expectations are for in-line market performance rather than continued outperformance.